Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Introduction to Hemostasis01:05

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

High glucose-primed HUVEC-derived extracellular vesicles encapsulated in microgels boost diabetic ischaemic flap regeneration via HIF-1α/VEGF pathway.

Journal of nanobiotechnology·2026
Same author

Injectable chondroitin sulfate-glycosylated decellularized extracellular matrix microgels activate Wnt/β-Catenin signaling to promote functional muscle regeneration in VML.

Bioactive materials·2026
Same author

Hierarchical microtopology and phase-specific delivery functionally restore ultralong nerve continuity across species.

Science advances·2026
Same author

Development of a vascularized multi-organoid-on-a-chip to model the heart-islet axis in diabetic cardiomyopathy.

Bioactive materials·2026
Same author

Phosphatidylserine-everted erythrocyte membrane vesicles enhance efferocytosis and remodeling of vascular grafts.

Nature communications·2026
Same author

Betaine based organ preservation solution alleviates renal allograft I/R injury by protecting endothelial cells.

Regenerative biomaterials·2026

関連する実験動画

Updated: May 16, 2026

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells
10:10

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells

Published on: October 27, 2009

表面誘発の水溶解は,血小板の集積を阻害する.

Wenting Zheng1, Jie Gao, Lijie Song

  • 1State Key Laboratory of Medicinal Chemical Biology and College of Life Sciences, Nankai University, Tianjin 300071, PR China.

Journal of the American Chemical Society
|December 18, 2012
PubMed
まとめ
この要約は機械生成です。

新種のトリペプチド水分誘導体であるNap-FFGは,血小板に選択的に自己組織化し,血小板の集積を阻害する. この発見は,医学と疾病管理における分子ヒドロゲルの応用のための新しい道を開く.

さらに関連する動画

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

関連する実験動画

Last Updated: May 16, 2026

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells
10:10

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells

Published on: October 27, 2009

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

科学分野:

  • バイオマテリアル科学 バイオマテリアル科学
  • ナノテクノロジー ナノテクノロジー
  • バイオケミストリー バイオケミストリー

背景:

  • 血小板の集積は,血栓形成および血静性において極めて重要です.
  • 分子ヒドロゲルは,標的を絞った生物医学介入の可能性を秘めています.
  • 血小板抑制のための選択剤の開発は,重要な治療目標です.

研究 の 目的:

  • 三ペプチドヒドロゲレーター,Nap-FFGが血小板表面に選択的に自己組織化することを調査する.
  • Nap-FFGの抗血小板凝集効果を評価する.
  • より広範な生物医学アプリケーションにおけるNap-FFGの潜在能力を探求する.

主な方法:

  • トリペプチド水素ゲレータの合成と特徴付け.
  • 血小板の集積抑制 (ADP,コラーゲン,トロンビン,アラキドン酸) のインビトロアッセイ.
  • LC-MS,コンフォカル顕微鏡,およびクリオ-TEMを用いた表面分析.
  • ゼータポテンシャル測定.
  • NIH 3T3細胞を用いた細胞表面結合研究.

主要な成果:

  • Nap-FFGはヒトの血小板に選択的に自己組み立てられ,IC50値が低い様々な集積経路を阻害する.
  • 他のNAP-FFXアナログは,抑制作用が著しく少なく,または全くなかった.
  • Cryo-TEMでは,Nap-FFGで処理された血小板の周りに自己組み立てられたナノファイバーが検出されました.
  • Nap-FFGは,NIH 3T3細胞と比較して,血小板に対するより高い親和性を示し,選択的結合を示唆しました.
  • Nap-FFGによる血小板の表面水凝縮が観察されました.

結論:

  • Nap-FFGは,選択的な血小板表面ヒドロゲレーターとして作用し,未知のリガンド受容体相互作用を通じて血小板の集積を効果的に抑制します.
  • この発見は,生物医学的な応用のための分子ヒドロゲルの有用性を拡大します.
  • Nap-FFGは,病原体の表面水溶解による感染症との闘いを含む,潜在的な治療的介入のための新しい戦略を提示しています.